SCHEMBL5136818

SCHEMBL5136818

CCCCn1c(CN(Cc2ccc(OC(C)C)cc2)Cc2cccc3ccccc23)cnc1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.41
PPARA Q07869 3/20 0.41
NPBWR1 P48145 1/20 0.36
TSHR P16473 2/20 0.34
C5AR1 P21730 1/20 0.34
MAPT P10636 2/20 0.33
HSD11B1 P28845 2/20 0.32
CYP2C19 P33261 1/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
RAB9A P51151 1/20 0.32
CNR2 P34972 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135533 0.91 PPARG (0.44) PPARGPPARANPBWR1TSHRC5AR1
SCHEMBL5134565 0.91 PPARG (0.42) PPARGPPARANPBWR1TSHRC5AR1
SCHEMBL5137996 0.90 TSHR (0.41) PPARGPPARATSHRC5AR1MAPT
SCHEMBL5072389 0.90 TSHR (0.41) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5136060 0.89 CASR (0.40) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5137298 0.89 PPARG (0.39) PPARGPPARANPBWR1TSHRC5AR1
SCHEMBL5072207 0.89 PPARG (0.39) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5135150 0.88 HSD11B1 (0.40) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5137554 0.87 MAPT (0.38) PPARGPPARATSHRC5AR1MAPT
SCHEMBL5136045 0.85 PPARG (0.37) PPARGPPARANPBWR1TSHRC5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed